Serum Peptide Profiling using MALDI Mass Spectrometry

Blood represents a convenient diagnostic specimen for clinical analysis. Serum metabolites and peptides have the potential to serve as reliable indicators of progression from a normal to a diseased state. However, the presence of salts, lipids and high concentrations of protein in blood serum can adversely affect its mass spectrometric profiling, as all of these moieties can hinder the ionisation and detection of diagnostic biomarkers. Several pre‐fractionation strategies using chromatographic adsorbents have been employed to desalt samples and remove abundant proteins such as albumin and immunoglobulin. As an alternative to multi‐stage fractionation chromatography, we describe in this practical review the adaptation and validation of a simple and fast solid‐phase extraction technique using ZipTips. The protocol allows for the purification and concentration of peptides in a few, mostly automated steps, prior to spectral biomarker pattern diagnostics using MALDI MS and MS/MS. It has the added advantages of being suitable for use in a high‐throughput and potentially clinical environment, only requiring a few microlitres of serum. We have evaluated, optimised, and standardised a number of analytical parameters ranging from serum storage and handling to automated peptide extraction, crystallisation, spectral acquisition, and signal processing. Using standardised protocols the average CV of serum profiles within‐ and between‐run replicates has been evaluated and found to be around 10 % based on the variability of all detected peaks (more than 100 peaks per profile). The results show that this easy and fast method of using ZipTips, tested over a whole year, is more reproducible and more suitable for serum profile screening than magnetic bead‐based methodologies which show higher variability and higher rates of rejected, low‐quality spectra upon applying strict data quality control filters.

[1]  A. Yocum,et al.  Effect of immunoaffinity depletion of human serum during proteomic investigations. , 2005, Journal of proteome research.

[2]  D. S. Hage,et al.  Obtaining high sequence coverage in matrix-assisted laser desorption time-of-flight mass spectrometry for studies of protein modification: analysis of human serum albumin as a model. , 2006, Analytical biochemistry.

[3]  A. Olshen,et al.  Differential exoprotease activities confer tumor-specific serum peptidome patterns. , 2005, The Journal of clinical investigation.

[4]  André M Deelder,et al.  Reliability of human serum protein profiles generated with C8 magnetic beads assisted MALDI-TOF mass spectrometry. , 2005, Analytical chemistry.

[5]  E. Diamandis Mass Spectrometry as a Diagnostic and a Cancer Biomarker Discovery Tool , 2004, Molecular & Cellular Proteomics.

[6]  P. Tempst,et al.  Serum Peptidome Patterns That Distinguish Metastatic Thyroid Carcinoma from Cancer-free Controls Are Unbiased by Gender and Age*S , 2006, Molecular & Cellular Proteomics.

[7]  T. Yip,et al.  New desorption strategies for the mass spectrometric analysis of macromolecules , 1993 .

[8]  Jeffrey R. Whiteaker,et al.  Head-to-head comparison of serum fractionation techniques. , 2007, Journal of proteome research.

[9]  T. M. Thomas,et al.  Depletion of the highly abundant protein albumin from human plasma using the Gradiflow , 2003, Proteomics.

[10]  K Chapman,et al.  The ProteinChip Biomarker System from Ciphergen Biosystems: a novel proteomics platform for rapid biomarker discovery and validation. , 2001, Biochemical Society transactions.

[11]  R. Tollenaar,et al.  MALDI-TOF Serum Protein Profiling for the Detection of Breast Cancer , 2006, Oncology Research and Treatment.

[12]  Thomas P Conrads,et al.  SELDI-TOF MS for diagnostic proteomics. , 2003, Analytical chemistry.

[13]  S. Weinberger,et al.  Current developments in SELDI affinity technology. , 2004, Mass spectrometry reviews.

[14]  Rency S Varghese,et al.  Enrichment of low molecular weight fraction of serum for MS analysis of peptides associated with hepatocellular carcinoma , 2006, Proteomics.

[15]  M. Guilhaus,et al.  Two‐dimensional liquid chromatography/tandem mass spectrometry analysis of Gradiflow™ fractionated native human plasma , 2005, Proteomics.

[16]  Pär Stattin,et al.  Correspondence re: B-L. Adam et al., Serum protein fingerprinting coupled with a pattern-matching algorithm distinguishes prostate cancer from benign prostate hyperplasia and healthy men. Cancer Res., 62: 3609-3614, 2002. , 2003, Cancer research.

[17]  Jeffrey S. Morris,et al.  Serum proteomics profiling—a young technology begins to mature , 2005, Nature Biotechnology.

[18]  E. Holland,et al.  Serum peptide profiling by magnetic particle-assisted, automated sample processing and MALDI-TOF mass spectrometry. , 2004, Analytical chemistry.

[19]  Ronald J. Moore,et al.  Toward a Human Blood Serum Proteome , 2002, Molecular & Cellular Proteomics.

[20]  M. Gustafsson,et al.  Integrated sample preparation and MALDI mass spectrometry on a microfluidic compact disk. , 2004, Analytical chemistry.

[21]  Eugene A. Kapp,et al.  Overview of the HUPO Plasma Proteome Project: Results from the pilot phase with 35 collaborating laboratories and multiple analytical groups, generating a core dataset of 3020 proteins and a publicly‐available database , 2005, Proteomics.

[22]  Wayne F. Patton,et al.  A novel, high-throughput workflow for discovery and identification of serum carrier protein-bound peptide biomarker candidates in ovarian cancer samples. , 2007, Clinical chemistry.

[23]  Emanuel F Petricoin,et al.  Serum proteomics in cancer diagnosis and management. , 2004, Annual review of medicine.

[24]  P. Schellhammer,et al.  Serum protein fingerprinting coupled with a pattern-matching algorithm distinguishes prostate cancer from benign prostate hyperplasia and healthy men. , 2002, Cancer research.

[25]  K. Kozak,et al.  Identification of biomarkers for ovarian cancer using strong anion-exchange ProteinChips: Potential use in diagnosis and prognosis , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[26]  S. Hanash,et al.  Challenges in deriving high-confidence protein identifications from data gathered by a HUPO plasma proteome collaborative study , 2006, Nature Biotechnology.

[27]  P. Tempst,et al.  Automated serum peptide profiling , 2006, Nature Protocols.

[28]  Chun-Ta Liao,et al.  Oral cancer plasma tumor marker identified with bead-based affinity-fractionated proteomic technology. , 2005, Clinical chemistry.

[29]  Erika Check,et al.  Proteomics and cancer: Running before we can walk? , 2004, Nature.

[30]  S. Baumann,et al.  Standardized approach to proteome profiling of human serum based on magnetic bead separation and matrix-assisted laser desorption/ionization time-of-flight mass spectrometry. , 2005, Clinical chemistry.

[31]  Hong Wang,et al.  A wide range of protein isoforms in serum and plasma uncovered by a quantitative intact protein analysis system , 2005, Proteomics.

[32]  D. Chan,et al.  Proteomics and bioinformatics approaches for identification of serum biomarkers to detect breast cancer. , 2002, Clinical chemistry.

[33]  B. Davis,et al.  LC-MS/MS Quantification of Zn-α2 Glycoprotein: A Potential Serum Biomarker for Prostate Cancer , 2007 .

[34]  Douglas C Pearl,et al.  Proteomic patterns in serum and identification of ovarian cancer , 2002, The Lancet.

[35]  Tomas Bergman,et al.  Identification of Endothelial Proteins by MALDI-MS Using a Compact Disc Microfluidic System , 2004, The protein journal.

[36]  E. Diamandis Point: Proteomic patterns in biological fluids: do they represent the future of cancer diagnostics? , 2003, Clinical chemistry.

[37]  S. Weinberger,et al.  Recent trends in protein biochip technology. , 2000, Pharmacogenomics.

[38]  D. Speicher,et al.  Depletion of multiple high‐abundance proteins improves protein profiling capacities of human serum and plasma , 2005, Proteomics.

[39]  B. Ye,et al.  Recent technical strategies to identify diagnostic biomarkers for ovarian cancer , 2007, Expert review of proteomics.

[40]  T. Ried,et al.  Sequential proteome alterations during genesis and progression of colon cancer , 2004, Cellular and Molecular Life Sciences CMLS.

[41]  E. Marchiori,et al.  Sample handling for mass spectrometric proteomic investigations of human sera. , 2005, Analytical chemistry.

[42]  E. Petricoin,et al.  Use of proteomic patterns in serum to identify ovarian cancer , 2002, The Lancet.

[43]  Min-Seok Kwon,et al.  Efficient prefractionation of low‐abundance proteins in human plasma and construction of a two‐dimensional map , 2005, Proteomics.

[44]  P. Tempst,et al.  Correcting common errors in identifying cancer-specific serum peptide signatures. , 2005, Journal of proteome research.

[45]  W. Barrett,et al.  Differences among techniques for high‐abundant protein depletion , 2005, Proteomics.

[46]  N. Anderson,et al.  The Human Plasma Proteome , 2002, Molecular & Cellular Proteomics.

[47]  Cornelis J H van de Velde,et al.  Detection of colorectal cancer using MALDI-TOF serum protein profiling. , 2006, European journal of cancer.

[48]  A. Sinaiko,et al.  Plasma protein profiling: Unique and stable features of individuals , 2005, Proteomics.

[49]  Ronald J Moore,et al.  Characterization of the human blood plasma proteome , 2005, Proteomics.

[50]  E. Petricoin,et al.  Early detection: Proteomic applications for the early detection of cancer , 2003, Nature Reviews Cancer.

[51]  N. Heegaard,et al.  Unravelling in vitro variables of major importance for the outcome of mass spectrometry-based serum proteomics. , 2007, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.